showed that CXCL12 enhances the resistance of chronic myelogenous leukemia cells to Adriamycin by increasing the expression of CXCR4 and activating the downstream AKT/NF-κB pathway.39 Here, CXCL12 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.